HYPR (Hyperfine Medical) Rasio tanggungan utang jangka dawa marang modal

Logo korporat perusahaan Hyperfine, Inc. (HYPR)

Hyperfine, Inc. (HYPR) production of mobile MRI systems is vulnerable due to its reliance on Asian chip supplies and trade conflicts. Growth is further hindered by clinic inertia, high assembly costs, and regulatory barriers. This chart illustrates the price trajectory of the asset with the 0.35 indicator. Meanwhile, the company adheres to standard environmental norms, striving to reduce energy consumption during the operation of its devices.

Hyperfine (HYPR): Utang jangka dawa marang modal saka 04.07.2022 nganti 28.10.2026
Produk merek Hyperfine Corp

The development of energy-efficient portable MRI systems within the ESG strategy of Hyperfine, Inc. (HYPR) requires significant R&D capital expenditures. By analyzing the long-term debt-to-equity ratio, an investor assesses the proportion of liabilities with maturities exceeding one year relative to equity, which determines the degree of financial autonomy and the business's resilience to long-term default risks during technology scaling.

Pesaing utama

Rasio utang jangka dawa marang modal Abbott Labs|TMO (Thermo Fisher Corp) - Utang jangka dawa marang modal|Rasio tanggungan utang jangka dawa marang modal GE HealthCare Inc. (GEHC)|Utang jangka dawa marang modal MTD (Mettler-Toledo International)|Utang jangka dawa marang modal waters.com WAT|Utang jangka dawa marang modal TECH|BRKR: Tanggungan utang jangka dawa marang ekuitas|Utang jangka dawa marang ekuitas Azenta Life Sciences|VREX (Varex Imaging Corp.) - Rasio utang jangka dawa marang modal|Utang jangka dawa marang ekuitas SMLR (Semler Scientific, Inc.)|Kewajiban jangka dawa marang modal BFLY|MLAB (Mesa Labs) - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka dawa marang modal Quantum-Si Inc. QSI|Rasio utang jangka dawa marang ekuitas Nanox (NNOX)|Rasio silihan jangka dawa marang modal Quanterix Inc QTRX|Utang jangka dawa marang modal MASS (908 Devices Inc.)|CV - Rasio tanggungan utang jangka dawa marang modal|MXCT (MaxCyte) - Utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas Rapid Micro Biosystems, Inc.|SEER - Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal FONR|Utang jangka dawa marang ekuitas DXR (Daxor Corporation)|Rasio utang jangka dawa marang ekuitas Spectral AI Inc. (MDAI)|VIVS: Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Aclarion Inc ACON|Akoya (AKYA) - Utang jangka dawa marang modal|THMO - Rasio utang jangka dawa marang modal|talis.bio - Utang jangka dawa marang modal|t2biosystems.com (TTOO) - Rasio tanggungan utang jangka dawa marang modal